PT2968302T - Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc - Google Patents

Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc

Info

Publication number: PT2968302T
Authority: PT; Portugal
Prior art keywords: ribavirin; combination; antiviral agents; direct acting; treating hcv
Prior art date: 2013-03-14

Application number

PT147258123T

Other languages

English (en)

Inventor

M Bernstein Barry

M Menon Rajeev

Mensing Sven

M Awni Walid

Liu Wei

Dutta Sandeep

J Podsadecki Thomas

L Campbell Andrew

Wei Lin Chih

Wang Tianli

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2014-03-14

Publication date

2018-01-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2968302(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Abbvie Inc filed Critical Abbvie Inc

2018-01-03 Publication of PT2968302T publication Critical patent/PT2968302T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT147258123T 2013-03-14 2014-03-14 Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc PT2968302T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361783437P	2013-03-14	2013-03-14

Publications (1)

Publication Number	Publication Date
PT2968302T true PT2968302T (pt)	2018-01-03

Family

ID=50771575

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147258123T PT2968302T (pt)	2013-03-14	2014-03-14	Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc

Country Status (27)

Country	Link
US (1)	US20140274934A1 (pt)
EP (4)	EP3733180A1 (pt)
JP (3)	JP6563894B2 (pt)
KR (2)	KR101853605B1 (pt)
CN (3)	CN105007921B (pt)
AU (3)	AU2014239322B2 (pt)
BR (1)	BR112015020918A2 (pt)
CA (1)	CA2901818C (pt)
CY (1)	CY1121474T1 (pt)
DK (1)	DK2968302T3 (pt)
EA (2)	EA201890507A1 (pt)
ES (1)	ES2654109T3 (pt)
HK (2)	HK1213191A1 (pt)
HR (1)	HRP20171898T1 (pt)
HU (1)	HUE036069T2 (pt)
IL (2)	IL240445B (pt)
LT (1)	LT2968302T (pt)
MX (1)	MX2015012536A (pt)
NO (1)	NO3090119T3 (pt)
PL (1)	PL2968302T4 (pt)
PT (1)	PT2968302T (pt)
RS (1)	RS56735B1 (pt)
SG (2)	SG10201709840UA (pt)
SI (1)	SI2968302T1 (pt)
TW (2)	TWI678205B (pt)
WO (1)	WO2014152635A1 (pt)
ZA (1)	ZA201705080B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
CN105007921B (zh) *	2013-03-14	2018-12-11	艾伯维公司	用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合
CN105658219A (zh) *	2013-10-25	2016-06-08	艾伯维公司	用于治疗hcv的方法
EP3082808A1 (en) *	2013-12-19	2016-10-26	AbbVie Inc.	Methods for treating liver transplant recipients
MX2016012722A (es) *	2014-04-02	2016-12-16	Abbvie Inc	Metodos para tratar el virus de la hepatitis c.
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
DK3383662T3 (da)	2016-01-08	2020-10-26	Entrust Datacard Corp	Kortudskrivningsmekanisme med kortreturneringsvej
US11192914B2 (en)	2016-04-28	2021-12-07	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
AU2017332771A1 (en) *	2016-09-23	2019-04-04	Abbvie Inc.	Dose adjustment
JP2018131439A (ja) *	2017-02-14	2018-08-23	アッヴィ・インコーポレイテッド	Ｈｃｖを処置する方法
CA2981993A1 (en) *	2017-08-02	2019-02-02	Abbvie Inc.	Methods for treating hcv
CN108329332A (zh) *	2018-03-16	2018-07-27	安徽华昌高科药业有限公司	一种制备Glecaprevir的方法
CN112351799A (zh) *	2018-04-10	2021-02-09	阿堤亚制药公司	具有硬化的hcv感染患者的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20110053327A (ko) *	2008-06-10	2011-05-20	얀센 파마슈티카 엔.브이.	텔라프레비르 투여 방식
CN102333772B (zh) *	2009-06-11	2013-12-11	雅培制药有限公司	抗病毒化合物
US8937150B2 (en) *	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
SG188618A1 (en) *	2010-09-21	2013-04-30	Enanta Pharm Inc	Macrocyclic proline derived hcv serine protease inhibitors
CH707029B1 (de)	2011-10-21	2015-03-13	Abbvie Inc	Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en)	2011-10-21	2014-10-02	Abbvie Ireland Unlimited Company	Methods for treating HCV
CN105007921B (zh)	2013-03-14	2018-12-11	艾伯维公司	用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合

2014
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/zh not_active Expired - Fee Related
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-03-14 EA EA201890507A patent/EA201890507A1/ru unknown
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/hu unknown
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/zh active Pending
- 2014-03-14 RS RS20171264A patent/RS56735B1/sr unknown
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/es active Active
- 2014-03-14 TW TW103109528A patent/TWI678205B/zh not_active IP Right Cessation
- 2014-03-14 EA EA201591701A patent/EA030482B1/ru not_active IP Right Cessation
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en active Application Filing
- 2014-03-14 PT PT147258123T patent/PT2968302T/pt unknown
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/ko active IP Right Grant
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/lt unknown
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/es unknown
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/ja not_active Expired - Fee Related
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/ko active IP Right Grant
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/pt not_active Application Discontinuation
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 TW TW108114285A patent/TW202002979A/zh unknown
- 2014-03-14 PL PL14725812T patent/PL2968302T4/pl unknown
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/zh active Pending
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
2016
- 2016-02-02 HK HK16101220.2A patent/HK1213191A1/zh not_active IP Right Cessation
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 HR HRP20171898TT patent/HRP20171898T1/hr unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/el unknown
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/zh unknown
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/ja active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/ja active Pending
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUE036069T2 (hu)	2018-06-28
CA2901818A1 (en)	2014-09-25
EP3733180A1 (en)	2020-11-04
JP2019214585A (ja)	2019-12-19
HRP20171898T1 (hr)	2018-04-06
JP2019167347A (ja)	2019-10-03
AU2014239322B2 (en)	2018-04-05
MX2015012536A (es)	2016-01-12
EP3915559A1 (en)	2021-12-01
US20140274934A1 (en)	2014-09-18
TW202002979A (zh)	2020-01-16
AU2014239322A1 (en)	2015-08-27
SG10201709840UA (en)	2018-01-30
ES2654109T3 (es)	2018-02-12
CA2901818C (en)	2021-05-04
EA201890507A1 (ru)	2018-07-31
IL267927A (en)	2019-09-26
EP2968302A1 (en)	2016-01-20
IL240445A0 (en)	2015-09-24
JP6563894B2 (ja)	2019-08-21
NO3090119T3 (pt)	2018-03-31
SI2968302T1 (en)	2018-04-30
EP2968302B9 (en)	2019-02-13
KR20150129035A (ko)	2015-11-18
HK1255257A1 (zh)	2019-08-09
ZA201705080B (en)	2019-02-27
AU2018202581B2 (en)	2019-12-05
CN105007921B (zh)	2018-12-11
RS56735B1 (sr)	2018-03-30
LT2968302T (lt)	2017-12-27
SG11201507361YA (en)	2015-10-29
KR101853605B1 (ko)	2018-05-03
EP2968302B1 (en)	2017-09-06
CN108187056A (zh)	2018-06-22
HK1213191A1 (zh)	2016-06-30
CN105007921A (zh)	2015-10-28
EA201591701A1 (ru)	2016-02-29
WO2014152635A9 (en)	2014-12-11
KR20180045055A (ko)	2018-05-03
EP3318258A1 (en)	2018-05-09
TWI678205B (zh)	2019-12-01
PL2968302T3 (pl)	2018-04-30
JP2016513703A (ja)	2016-05-16
AU2020201656A1 (en)	2020-03-26
IL240445B (en)	2019-07-31
EA030482B1 (ru)	2018-08-31
CY1121474T1 (el)	2020-05-29
TW201505633A (zh)	2015-02-16
AU2018202581A1 (en)	2018-05-10
EP3318258B1 (en)	2020-05-13
CN109908353A (zh)	2019-06-21
PL2968302T4 (pl)	2018-04-30
BR112015020918A2 (pt)	2017-07-18
DK2968302T3 (en)	2017-12-18
WO2014152635A1 (en)	2014-09-25

Publication	Publication Date	Title
IL267927A (en)	2019-09-26	A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients
IL264541B (en)	2019-09-26	The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
HRP20181863T1 (hr)	2018-12-28	Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20170945T1 (hr)	2017-09-22	Sulfamoil-arilamidi i njihova uporaba kao lijekova za liječenje hepatitisa b
HK1217330A1 (zh)	2017-01-06	-苯基-氨甲酰衍生物及其作爲藥物用於治療乙型肝炎的用途
EP2953456A4 (en)	2016-07-20	TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP2953462A4 (en)	2016-07-20	TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE FOR THE TREATMENT OF HEPATITIS C
EP2953461A4 (en)	2016-07-20	TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
AP2015008814A0 (en)	2015-10-31	Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b